Related Experiment Video
Updated: May 22, 2025
08:58
Analyzing Beneficial Effects of Nutritional Supplements on Intestinal Epithelial Barrier Functions During Experimental Colitis
Published on: January 5, 2017
12.2K
Novel outcomes in inflammatory bowel disease
Vipul Jairath1,2, Neeraj Narula3, Ryan C Ungaro4
1Department of Medicine, Division of Gastroenterology, Western University, London, ON, Canada.
Journal of Crohn'S & Colitis
|March 13, 2025
Summary
Novel endpoints in inflammatory bowel diseases (IBD) trials, including Crohn
Area of Science:
- Gastroenterology and immunology
- Clinical trial methodology
- Inflammatory Bowel Disease (IBD) research
Background:
- Inflammatory bowel diseases (IBD), including Crohn's disease (CD) and ulcerative colitis (UC), are chronic conditions requiring long-term management.
- Traditional treatment evaluation focused on short-term outcomes like symptom relief and clinical remission.
- Advancements in therapies necessitate evaluating novel outcomes for comprehensive disease management.
Purpose of the Study:
- To review novel endpoints used in clinical trials for IBD treatments.
- To assess the value of these endpoints in evaluating disease activity and modification.
- To explore their predictive value for long-term complications and morbidities.
Main Methods:
- Analysis of published clinical studies involving patients with UC and CD treated with biologics or small molecule therapies.
- Identification and discussion of novel IBD endpoints utilized in these trials.
- Evaluation of the significance of these endpoints for assessing treatment efficacy.
Main Results:
- Biologics and small molecule therapies are being evaluated using novel endpoints beyond symptom control.
- Emerging endpoints include patient-reported outcomes, transmural healing, and disease clearance.
- These novel measures offer deeper insights into remission states and disease modification.
Conclusions:
- Novel endpoints are crucial for a comprehensive assessment of IBD treatment efficacy.
- These endpoints provide a more accurate reflection of deeper remission and disease modification.
- Utilizing novel endpoints can better predict long-term outcomes and reduce patient morbidity.
More Related Videos
Related Concept Videos
01:29Inflammatory Bowel Disease IV: Pharmacological Management
84
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
84
01:30Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
290
Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
290
01:30Inflammatory Bowel Disease II: Crohn's Disease
151
Introduction
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by...
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by...
151
01:21Inflammatory Bowel Disease V: Surgical Management
77
Surgical interventions for inflammatory bowel disease (IBD), which includes ulcerative colitis and Crohn's disease, are essential in managing symptoms and addressing complications. The selection of surgical procedures is contingent upon the specific conditions and complications that stem from these illnesses.
Here are some common surgical interventions for IBD:
Here are some common surgical interventions for IBD:
77
01:27Inflammatory Bowel Disease I: Ulcerative Colitis
106
Introduction
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
106
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
107
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
107